A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease

References

• Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science 2011;332:1519–23.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011;60:313–26.
   PubMed Web of Science ®Google Scholar
• Lemoine M, Ratziu V, Kim M, Maachi M, Wendum D, Paye F, Bastard JP, Poupon R, Housset C, Capeau J, Serfaty L. Serum adipokine levels predictive of liver injury in non- alcoholic fatty liver disease. Liver Int 2009;29:1431–8.
   PubMed Web of Science ®Google Scholar
• Centis E, Marzocchi R, Di Domizio S, Ciaravella MF, Marchesini G. The effect of lifestyle changes in non- alcoholic fatty liver disease. Dig Dis 2010;28:267–73.
   Google Scholar
• Oza N, Eguchi Y, Mizuta T, Ishibashi E, Kitajima Y, Horie H, Ushirogawa M, Tsuzura T, Nakashita S, Takahashi H, Kawaguchi Y, Oda Y, Iwakiri R, Ozaki I, Eguchi T, Ono N, Fujimoto K. A pilot trial of body weight reduction for nonalcoholic fatty liver disease with a home-based lifestyle modification intervention delivered in collaboration with interdisciplinary medical staff. J Gastroenterol 2009;44: 1203–18.
   Google Scholar
• Bellentani S, Dalle Grave R, Suppini A, Marchesini G; Fatty Liver Italian Network. Behavior therapy for nonalcoholic fatty liver disease: the need for a multidisciplinary approach. Hepatology 2008;47:746–54.
   PubMed Web of Science ®Google Scholar
• Oh-I S, Shimizu H, Satoh T, Okada S, Adachi S, Inoue K, Eguchi H, Yamamoto M, Imaki T, Hashimoto K, Tsuchiya T, Monden T, Horiguchi K, Yamada M, Mori M. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006;443:709–12.
   PubMed Web of Science ®Google Scholar
• Ramanjaneya M, Chen J, Brown JE, Tripathi G, Hallschmid M, Patel S, Kern W, Hillhouse EW, Lehnert H, Tan BK, Randeva HS. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 2010;151: 3169–80.
   PubMed Web of Science ®Google Scholar
• Stengel A, Taché Y. Nesfatin-1– role as possible new potent regulator of food intake. Regul Pept 2010;163:18–23.
   PubMed Web of Science ®Google Scholar
• Nakata M, Manaka K, Yamamoto S, Mori M, Yada T. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca[2 +] influx through L-type channels in mouse islet β-cells. Endocr J 2011;58:305–13.
   PubMed Web of Science ®Google Scholar
• Tanida M, Mori M. Nesfatin-1 stimulates renal sympathetic nerve activity in rats. Neuroreport 2011;22:309–12.
   PubMed Web of Science ®Google Scholar
• Özsavcí D, Erşahin M, Şener A, Özakpinar ÖB, Toklu HZ, Akakín D, Şener G, Yeğen BÇ. The novel function of nesfatin-1 as an anti-inflammatory and antiapoptotic peptide in subarachnoid hemorrhage-induced oxidative brain damage in rats. Neurosurgery 2011;68:1699–1708.
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, Kato T, Takeda N, Okuda J, Ida K, Kawahito Y, Yoshikawa T, Okanoue T. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007;12:2708–15.
   Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487–95.
   PubMed Web of Science ®Google Scholar
• Stengel A, Goebel M, Taché Y. Nesfatin-1: a novel inhibitory regulator of food intake and body weight. Obes Rev 2011;12:261–71.
   PubMed Web of Science ®Google Scholar
• Stengel A, Taché Y. Minireview: nesfatin-1--an emerging new player in the brain-gut, endocrine, and metabolic axis. Endocrinology. 201;152:4033–8.
   Google Scholar
• Stengel A, Goebel M, Yakubov I, Wang L, Witcher D, Coskun T, Taché Y, Sachs G, Lambrecht NW. Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 2009;150:232–8.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Oh-I S, Hashimoto K, Nakata M, Yamamoto S, Yoshida N, Eguchi H, Kato I, Inoue K, Satoh T, Okada S, Yamada M, Yada T, Mori M. Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin- independent mechanism. Endocrinology 2009;150:662–71.
   PubMed Web of Science ®Google Scholar
• Saldanha JF, Carrero JJ, Lobo JC, Stockler-Pinto MB, Leal VO, Calixto A, Geloneze B, Mafra D. The newly identified anorexigenic adipokine nesfatin-1 in hemodialysis patients: are there associations with food intake, body composition and inflammation? Regul Pept 2012;173:82–5.
   PubMedGoogle Scholar
• Atsuchi K, Asakawa A, Ushikai M, Ataka K, Tsai M, Koyama K, Sato Y, Kato I, Fujimiya M, Inui A. Centrally administered nesfatin-1 inhibits feeding behaviour and gastroduodenal motility in mice. Neuroreport 2010;27;21:1008–11.
   Google Scholar
• Tsuchiya T, Shimizu H, Yamada M, Osaki A, Oh-I S, Ariyama Y, Takahashi H, Okada S, Hashimoto K, Satoh T, Kojima M, Mori M. Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin Endocrinol [Oxf] 2010;73:484–90.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li L, Yang M, Liu H, Boden G, Yang G. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2012;120:91–5.
   PubMed Web of Science ®Google Scholar
• Gonzalez R, Reingold BK, Gao X, Gaidhu MP, Tsushima RG, Unniappan S. Nesfatin-1 exerts a direct, glucose- dependent insulinotropic action on mouse islet β- and MIN6 cells. J Endocrinol 2011;208:9–16.
   PubMed Web of Science ®Google Scholar
• Foo KS, Brauner H, Ostenson CG, Broberger C. Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J Endocrinol 2010;204:255–63.
   PubMed Web of Science ®Google Scholar
• Su Y, Zhang J, Tang Y, Bi F, Liu JN. The novel function of nesfatin-1: anti-hyperglycemia. Biochem Biophys Res Commun 2010;391:1039–42.
   PubMed Web of Science ®Google Scholar
• Li QC, Wang HY, Chen X, Guan HZ, Jiang ZY. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept 2010;159:72–7.
   PubMed Web of Science ®Google Scholar